Annual General Meeting 2022

Annual General Meeting FY 2020/21

Documents for the Annual General Meeting on 9 March 2022

Item 1: Submission of the adopted separate annual financial statements and approved consolidated financial statements of BRAIN Biotech AG for FY 2020/21, the separate management report and Group management report for FY 2020/21 with the explanatory reports relating to disclosures pursuant to Sections 289a and 315a of the German Commercial Code (HGB), as well as the report by the Supervisory Board for FY 2020/21

 

Annual Report FY 2020/21 (full document) (PDF)

Group management report and Consolidated financial statements (from AR 2020/21) (PDF)

Company’s annual financial statement and management report 2020/21 (German version only) (PDF)

Explanatory report by the Executive Board regarding the information pursuant to §§ 289a, 315a of the German Commercial Code (HGB) for Fiscal Year 2020/21 (PDF)

Item 2: Resolution concerning discharging the Management Board for the FY 2020/21

The Management and Supervisory boards propose that the Management Board members in the fiscal year from 1 October 2020 to 30 September 2021 be discharged for this period.

Item 3: Resolution concerning discharging the Supervisory Board for the FY 2020/21

The Management and Supervisory boards propose that the Supervisory Board members in the fiscal year from 1 October 2020 to 30 September 2021 be discharged for this period.

Item 4: Election of the auditor of the separate financial statements and the auditor of the consolidated financial statements for the FY 2021/22

The Supervisory Board proposes electing

Baker Tilly Holding GmbH Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft, Frankfurt am Main,

to be the auditor of the separate and consolidated financial statements for the fiscal year from 1 October 2021 to 30 September 2022. For further details and information on the proposal, please refer to the invitation.

Item 5: Resolution concerning cancellation of Authorized Capital 2021 / I, the creation of a new Authorized Capital 2022 / I against cash and/or non-cash capital contributions with the authorization to exclude subscription rights as well as the related requisite bylaw amendment

Written report by the Management Board pursuant to Sections 203 (2) Clause 2, 186 (4) Clause 2 AktG relating to item 5 on the agenda concerning the reasons to authorize the Management Board to exclude shareholders’ subscription rights when utilizing Authorized Capital 2022 / I (PDF)

Countermotions

Countermotion 1 - Countermotion to Agenda Item 4 (PDF)

Statement on the counter-motion to agenda item 4 (PDF)